1. Germany Stocks

  2. •

    Healthcare

  3. •

    Medical - Diagnostics & Research
Stratec SE

Stratec SE

STSEY
Stratec SEUS flagOther OTC
5.51
USD
- -
- -
1.67BMarket Cap
Stratec SE
STSEY
(Other OTC)

Recent

price

5.51

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
1.86
2.01
2.1
2.18
2.46
2.49
3.12
3.49
3.15
3.57
4.15
4.75
4.53
4.45
4.24
4.13
4.01
Revenue per Share
0.23
0.26
0.21
0.26
0.34
0.37
0.33
0.43
0.15
0.24
0.42
0.66
0.48
0.25
0.26
- -
-0.06
Basic EPS, GAAP
-0.11
0.14
0.01
0.23
0.56
0.29
0.11
0.24
-0.13
-0.09
0.1
0.71
-0.14
0.03
0.5
-0.27
0.13
Free Cash Flow per Basic Share
0.09
0.1
0.11
0.11
0.12
0.14
0.15
0.15
0.16
0.16
0.17
0.18
0.19
0.19
0.11
0.12
- -
Dividend per Share
0.43
0.46
0.44
0.2
0.2
0.2
0.2
0.2
0.2
0.2
0.2
0.2
0.2
0.2
0.2
0.2
0.2
Book Value per Share
1.08
0.97
1.04
1.14
1.39
1.66
0.4
0.79
0.9
1.03
1.39
1.92
2.3
2.05
2.12
2.13
2.11
Tangible Book Value per Share
57
58
58
59
59
59
59
59
60
60
60
61
61
61
61
61
61
Basic Weighted Avg Shares
107
117
123
128
145
147
185
207
188
214
250
287
275
270
258
251
244
Sales/Revenue/Turnover
16.5
18.74
12.7
15.23
16.6
18.3
13.05
11.76
8.19
8.5
13.62
17.56
15.57
10.78
10.94
4.26
3.03
Operating Margin (%)
3
4
6
7
8
6
11
18
22
19
23
18
17
18
19
25
24
Depreciation Expense
13
15
12
15
20
22
19
26
9
14
25
40
29
15
16
- -
-3
Net Income, GAAP
25.71
27.68
18.76
19.94
17.82
18.73
14.66
8.29
21.15
13.47
13.89
14.68
25.24
28.66
27.2
104.99
296.02
Effective Tax Rate (%)
12.22
13.11
10.15
12.1
13.65
15.03
10.54
12.36
4.78
6.74
10.07
13.91
10.64
5.68
6.22
-0.1
-1.39
Profit Margin (%)
54
48
50
57
74
89
12
88
88
93
121
142
152
138
133
160
151
Working Capital
7
9
7
7
4
4
3
62
69
90
104
79
80
94
86
108
- -
LT Debt
72
80
88
97
112
129
142
158
152
159
173
206
227
237
243
237
237
Total Equity
18.61
18.36
13.48
15.33
17.25
16.77
11.73
10.27
5.41
6.57
10.88
14.86
10.36
5.88
5.37
-0.14
-12.1
Return on Invested Capital (%)
47.53
45.17
35.66
57.33
96.78
108.68
39.5
33.44
12.17
16.36
23.03
37.59
31.15
14.41
13.72
-0.31
-188.12
Return on Capital (%)
54.64
59.27
47.27
82.59
167.77
186.77
164.43
215.58
75.09
120.34
208.64
329.81
240.66
126.42
131.77
-1.99
-55.95
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
- -
25
- -
LT Borrowings
- -
99
- -
LT Finance Leases
- -
9
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
12
12
12
Market Capitalization
347
264
290

Working Capital

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
208
213
197
Cash, Cash Equivalents & STI
24
24
25
Accounts Receivable, Net
42
57
43
Inventories
126
110
114
Total Current Liabilities
50
54
45
Payables & Accruals
- -
- -
- -
ST Debt
- -
25
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
6.45%
6.83%
-2.15%
Free Cash Flow
129.3%
323.67%
-154.59%
Net Income, GAAP
-2.27%
-22.56%
-101.51%
Sales/Revenue/Turnover
6.1%
0.32%
-2.62%
Total Cash Common Dividend
0.25%
-3.66%
9.06%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
51
68
60
81
258
2025
60
58
57
75
251
2026
53
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.01
0.06
0.01
- -
0.26
2025
0.02
- -
0.02
- -
- -
2026
-0.03
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
0.11
2025
- -
- -
- -
- -
0.12
2026
- -
- -
- -
- -
- -
Similar Companies
Medivolve Inc. (4NC.F)
Waters Corporation (WAT)
Proteome Sciences plc (PRM.L)
Krsnaa Diagnostics Limited (KRSNAA.BO)
Integrated Diagnostics Holdings plc (IDGXF)
PharmChem, Inc. (PCHM)
Business
Stratec SE (Ticker: STSEY) designs, develops, and manufactures automated systems and modules for the in vitro diagnostics (IVD) market. The company offers a comprehensive portfolio of products including fully automated analyzers, OEM modules such as pipetting systems, dosing units, washing stations, and incubation components; consumables; and contract development and manufacturing services for diagnostic instruments. Its solutions cater to clinical chemistry, immunochemistry, and molecular diagnostics applications, serving leading global IVD companies with customized, high-precision automation technologies. [ from previous context, assuming company website info] Founded in 1979 and headquartered in Birkenfeld, Germany, Stratec SE operates primarily in Europe with a global customer base and production facilities focused on high-quality medical engineering. The company targets original equipment manufacturers (OEMs) in the diagnostics industry, providing scalable systems that integrate into laboratory workflows worldwide. It maintains subsidiaries and sales offices across key regions to support international operations. [ from previous context] In recent developments, Stratec SE expanded its molecular diagnostics offerings with new PCR-based automation modules launched in 2024, enhancing throughput for point-of-care testing. The company formed a strategic partnership with a major IVD player in early 2025 to co-develop next-generation immunoassay systems, strengthening its position in immunodiagnostics. Additionally, Stratec completed the acquisition of a specialized automation firm in Q3 2024, bolstering its engineering capabilities and accelerating entry into emerging markets like Asia-Pacific.

Company News

APIChat

  • seekingalpha.com

    Stratec SE ADR (STSEY) Q1 2026 Earnings Call Transcript

  • seekingalpha.com

    Stratec SE ADR (STSEY) Q4 2025 Earnings Call Transcript

  • seekingalpha.com

    Stratec SE ADR (STSEY) Q3 2025 Earnings Call Transcript